M. Docteur NICOLAS LECUYER

Bibliographie

• Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network

  2020

  ArticleJournal of Clinical Medicine

• Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study

  2019

  ArticleRheumatology and Therapy

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

• CABINET DU DR NICOLAS LECUYER

  POLICLINIQUE ST CLAUDE — 1 BD SCHWEITZER, 02109 Saint-Quentin

  Libéral

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Prevalence of Paget's disease of bone and spinal hemangioma in French women older than 75 years: data from the EPIDOS study

  Joint bone spine · 2000

  📚 14 citations
• 2

  Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study

  Rheumatology and therapy · 2019

  📚 12 citations🔓 Open Access📄 PDF gratuit ↗
• 3

  Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network

  Journal of clinical medicine · 2020

  📚 6 citations🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Objectives: Data on abatacept (ABA) persistence in routine practice are limited. We aimed to study ABA persistence rates at 12 months, according to the date of initiation, and to analyze the factors associated with persistence at 12 months. Methods: We performed an observational, ambispective, multi-center study from January 2008 to July 2016, based on the French-RIC Network. We defined three groups of patients followed up for rheumatoid arthritis (RA), according to the date of initiation of ABA therapy: Group 1 (from 2007 to 31 July 2010: ABA indicated after anti-TNF failure); Group 2 (from 1 August 2010 to 31 March 2014: ABA indicated after conventional antirheumatic drugs failure); Group 3 (from 1 April 2014 to 1 July 2016: ABA available by the subcutaneous injection). Results: Among 517 patients who initiated ABA, drug persistence at 12 months was 68%. The only factor significantly associated with persistence rate at 12 months was C-reactive protein (CRP) < 10 mg/L at ABA initiation (odds ratio (OR) 0.6, 95% confidence interval 0.3–0.9; p = 0.0016). There was no significant difference in drug persistence according to date of initiation, the line of biological disease-modifying antirheumatic drugs (bDMARD) therapy or the route of administration. Conclusions: In routine practice, over time, ABA has come to be initiated earlier in the course of therapy for RA in France. Abatacept persistence is similar to that reported in the Orencia Rheumatoid Arthritis (ORA) registry, and does not differ according to the date of initiation. The only factor found to be associated with the persistence rate at 12 months was CRP < 10 mg/L at ABA initiation.

Publications scientifiques (3) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Datasets & protocoles partagés

• Tocilizumab Effectiveness after Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis - The RoSwitch Study

  Image2019Adis Journals

  Full copyright for enhanced digital features is owned by the authors. <strong>Article full text</strong> <br> The full text of this article can be found <b>here</b>. <br> <br> <strong>Provide enhanced digital features fo

• Tocilizumab Effectiveness after Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis - The RoSwitch Study

  Image2019Adis Journals

  Full copyright for enhanced digital features is owned by the authors. <strong>Article full text</strong> <br> The full text of this article can be found <b>here</b>. <br> <br> <strong>Provide enhanced digital features fo

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche